Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2

被引：12

作者：

De Paoli P. ^{[1
,3
]}

Zanussi S. ^{[1
]}

Caggiari L. ^{[1
]}

Bortolin M.T. ^{[1
]}

D'Andrea M. ^{[1
]}

Simonelli C. ^{[2
]}

Tirelli U. ^{[2
]}

机构：

[1] Dept. of Microbiol., Immunol./Virol., Centro di Riferimento Oncologico, IRCCS, Aviano

[2] Dept. of Medical Oncology and AIDS, Centro di Riferimento Oncologico, IRCCS, Aviano

[3] Dept. of Microbiol., Immunol./Virol., Centro di Riferimento Oncologico, IRCCS

来源：

Journal of Clinical Immunology | 1999年 / 19卷 / 5期

关键词：

Highly active antiretroviral therapy; HIV infection; IL-16; IL-2; production; therapy;

D O I：

10.1023/A:1020547826191

中图分类号：

学科分类号：

摘要：

This study presents the kinetics of CD4/CD25 cell numbers, serum sCD25 levels, and intracellular production and release of interleukin-2 (IL-2) and interleukin-16 (IL-16) in 11 HIV+ patients treated with six cycles of highly active antiretroviral therapy (HAART) plus six MUI of subcutaneous IL-2 compared to 10 HIV+ patients treated with HAART alone. IL-2 therapy induced moderate effects on CD4 T cell recovery and increased CD4/CD25+ cells and sCD25 levels after 2 weeks, while intracellular and secreted IL-2 was reduced and IL-16 was increased at the same time point. After 24 weeks, while HAART- treated patients had increased IL-2 production, in IL-2 treated patients, cytokine production was unaltered compared to pretreatment values: Decreased in vitro IL-2 production may depend on a feedback inhibition by IL-2 infusion. Because of its known antiviral effects, the increased IL-16 production seen after 2 weeks in IL-2-treated individuals may produce beneficial effects on HIV disease. The kinetics of cytokine production may serve to define better the use IL-2 in clinical trials.

引用

页码：317 / 325

页数：8

共 37 条

[1]

Schwartz D.H., Skowron G., Merigan T.C., Safety and effects of interleukin-2 plus zidovudine in asymptomatic individuals infected with human immunodeficiency virus, J Acquir Immune Defic Syndr, 4, pp. 11-23, (1991)

[2]

Kovacs J.A., Baseler M., Dewar R.J., Vogel S., Davey R.T., Faloon J., Polis M.A., Walker R.E., Stevens R., Salzman N.P., Metcalf J.A., Masur H., Lane H.C., Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study, N Engl J Med, 332, pp. 567-575, (1995)

[3]

Leef Jacobson E., Pilaro F., Smith K.A., Rational interleukin 2 therapy for HIV positive individuals: Daily low doses enhance immune function without toxicity, Proc Natl Acad Sci USA, 93, pp. 1045-10410, (1996)

[4]

Teppler H., Kaplan G., Smith K.A., Montana A.L., Meyn P., Cohn Z.A., Prolonged immunostimulatory effect of low-dose polyethylene glicol interleukin 2 in patients with human immunodeficiency virus type 1 infection, J Exp Med, 177, pp. 483-492, (1993)

[5]

Scadden D.T., Cytokine use in the management of HIV diseuse, J. Acquir Immune Defic Syndr Human Retrovir, 16, (1997)

[6]

Kovacs J.A., Vogel S., Albert J.M., Falloon J., Davey R.T., Walker R.E., Polis M.A., Spooner K., Metcalf J.A., Baseler M., Fyfe G., Lane H.C., Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus, N Engl J Med, 335, pp. 1350-1356, (1996)

[7]

Davey R.D., Chaitt D.G., Piscitelli S.C., Wells M., Kovacs J., Walker R.E., Falloon J., Polis M.A., Metcalf J.A., Masur H., Fyfe G., Lane H.C., Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected person, J Infect Dis, 175, pp. 781-789, (1997)

[8]

Levy Y., Capitant C., Houhou S., Carriere I., Gaustault J.A., Viard J.P., Aboulker J.P., IL2 in HIV patients: A randomized trial comparing SC, PEG, CIV IL2 with AZT + ddi, 12th International Conference on AIDS, (1998)

[9]

Piscitelli S.C., Wells M.J., Metcalf J.A., Baseler M., Stevens R., Davey R., Pharmacokinetics and pharmacodynamics of subcutaneous interleukin-2 in HIV-infected patients, Pharmacotherapy, 16, pp. 754-759, (1996)

[10]

De Paoli P., Zunussi S., Simonelli C., Bortolin M.T., D'Andrea M., Crepaldi C., Talamini R., Comar M., Giacca M., Tirelli U., Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects, J Clin Invest, 100, pp. 2737-2743, (1997)

← 1 2 3 4 →